Roche’s scuttled anti-cholesterol drug may in fact be a viable treatment. PharmaTimes reports that researchers found that dalcetrapib, a cholesterylester transfer protein (aka CETP), helped patients with a specific genetic profile.
The medication works by increasing “good cholesterol” levels, and the Phase-III study showed the drug was associated with a reduced risk of events like heart attacks and stroke by 27% or 39%, depending on genetics.
